Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2016" report to their offering.

'SerineThreonine Protein Kinase ATR - Pipeline Review, H2 2016'; Serine

Threonine Protein Kinase ATR pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Serine/Threonine Protein Kinase ATR Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.

The report 'SerineThreonine Protein Kinase ATR - Pipeline Review, H2 2016' outlays comprehensive information on the Serine/Threonine Protein Kinase ATR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase ATR targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 4 respectively.

Key Topics Covered:

  1. Introduction
  2. Serine/Threonine Protein Kinase ATR Overview
  3. Therapeutics Development
  4. Pipeline Products for Serine/Threonine Protein Kinase ATR - Overview
  5. Pipeline Products for Serine/Threonine Protein Kinase ATR - Comparative Analysis
  6. Serine/Threonine Protein Kinase ATR - Therapeutics under Development by Companies
  7. Serine/Threonine Protein Kinase ATR - Therapeutics under Investigation by Universities/Institutes
  8. Serine/Threonine Protein Kinase ATR Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Serine/Threonine Protein Kinase ATR - Products under Development by Companies
  13. Serine/Threonine Protein Kinase ATR - Products under Investigation by Universities/Institutes
  14. Serine/Threonine Protein Kinase ATR - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • Vertex Pharmaceuticals Incorporated

For more information about this report visit http://www.researchandmarkets.com/research/8vdh6p/serinethreonine

Related Topics: Chemicals, Central Nervous System Drugs, Enzymes

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005823/en/

Business Wire
www.businesswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.